CED Life Science Conference 2018 - presenting at the Coulter Investment Forum
Year Founded: 2017
NephroDI Therapeutics, Inc. is an early-stage pharmaceutical company that focuses on concentration disorders of the kidney. The initial clinical indication for its orally administered lead small molecule is for Nephrogenic Diabetes Insipidus in children, a pediatric orphan indication. The Company is preparing to enter pre-clinical development with its lead drug candidate. An accelerated clinical development process is expected given the pediatric orphan indication. The product is potentially eligible for the FDA Rare Pediatric Disease Voucher.
Rachael Hagan, M.Sc., President & CEO
Jeff M. Sands, M.D., Director
Ish Khanna, Ph.D., Director
Janet D. Klein, Ph.D.
Ram Pillarisetti, Ph.D.
Donna See, Director
Rifat Pamukcu, MD, FAIMBE, Business & Scientific Advisor
KEY MILESTONES TO DATE
- $250K invested to date
- 2 issued patents, 3rd patent pending
- Lead drug candidate identified
- Proof of principle animal studies complete
- Dose range finding studies identified efficacious dose
- Manufacturing scaled up to 200 grams with optimized synthesis
Emory/GT Coulter Translational Fund
Georgia Research Alliance
Rachael Hagan, President & CEO
Philadelphia, PA/ Atlanta, GA
Learn more about the CED Life Science Conference.